Skip to content


  • Correction
  • Open Access

Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma

  • 1Email author,
  • 2,
  • 3,
  • 4,
  • 5,
  • 6,
  • 7,
  • 8,
  • 8,
  • 9,
  • 10,
  • 11,
  • 12,
  • 13,
  • 14,
  • 15,
  • 16,
  • 17,
  • 18,
  • 19,
  • 59,
  • 20,
  • 20,
  • 21,
  • 22,
  • 22,
  • 23,
  • 24,
  • 25,
  • 26,
  • 26,
  • 27,
  • 28,
  • 29,
  • 30,
  • 31,
  • 32,
  • 33,
  • 34,
  • 35,
  • 36,
  • 37,
  • 37,
  • 38,
  • 39,
  • 40,
  • 41,
  • 42,
  • 43,
  • 44,
  • 44,
  • 45,
  • 46,
  • 46,
  • 47,
  • 48,
  • 49,
  • 50,
  • 51,
  • 52,
  • 53,
  • 54,
  • 55,
  • 56,
  • 58,
  • 1,
  • 1,
  • 57 and
  • 58Email authorView ORCID ID profile
Journal of Translational Medicine201816:179

  • Received: 8 June 2018
  • Accepted: 19 June 2018
  • Published:

The original article was published in Journal of Translational Medicine 2018 16:142

Correction to: J Transl Med (2018) 16:142

Following publication of the original article [1], the authors reported an error in the spelling of one of the author names. In this Correction the incorrect and correct author names are indicated and the author name has been updated in the original publication. The authors also reported an error in the Methods section of the original article. In this Correction the incorrect and correct versions of the affected sentence are indicated. The original article has not been updated with regards to the error in the Methods section.

Incorrect author name upon publication:
  • Tobias Walpert

The correct author name:
  • Tobias Walbert

The affected sentence in the Methods section upon publication, with the error marked in bold:
  • In general, approximately 2 g of tumor tissue was needed to produce the full ten doses for the 36-month treatment and follow-up schedule. The vaccine was aliquoted in individual doses and cryopreserved at < 150 °C [22].

The corrected sentence, with the corrected temperature marked in bold:
  • In general, approximately 2 g of tumor tissue was needed to produce the full ten doses for the 36-month treatment and follow-up schedule. The vaccine was aliquoted in individual doses and cryopreserved at < − 150 °C [22].

The reference which is cited in the above sentence can be reviewed in the original article.



Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

University of California Los Angeles (UCLA) David Geffen School of Medicine & Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA
King’s College London School of Medical Education, London, UK
University of Florida, Gainesville, FL, USA
Washington University, St. Louis, MO, USA
Abbott Northwestern Hospital, Minneapolis, MN, USA
Swedish Medical Center, Swedish Neuroscience Institute, Seattle, WA, USA
University of Michigan Medical School, Ann Arbor, MI, USA
University of Kansas Cancer Center, Kansas City, KS, USA
Sutter Institute for Medical Research, Sacramento, CA, USA
Columbia University Medical Center, New York, NY, USA
Indiana University Simon Cancer Center, Indianapolis, IN, USA
Overlook Medical Center, Summit, NJ, USA
University of Rochester Medical Center, Rochester, NY, USA
Rush University Medical Center, Rochester, USA
Rutgers Cancer Institute, New Brunswick, NJ, USA
University of Cincinnati Medical Center, Cincinnati, OH, USA
Hackensack University Medical Center, Hackensack, NJ, USA
UC Irvine Medical Center, Irvine, CA, USA
Winthrop-University Hospital, Mineola, NY, USA
Rhode Island Hospital, Providence, RI, USA
University of Colorado Hospital, Aurora, CO, USA
Henry Ford Health System, Detroit, MI, USA
St. Thomas Research Institute, Nashville, TN, USA
University of Texas Health Science Center, San Antonio, TX, USA
University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
University of North Carolina, Chapel Hill, NC, USA
City of Hope National Medical Center, Duarte, CA, USA
Thomas Jefferson University, Philadelphia, PA, USA
St. Joseph Hospital, Newport Beach, CA, USA
Vanderbilt University, Nashville, TN, USA
Beth Israel Deaconess Medical Center, Boston, MA, USA
Baylor University Medical Center, Dallas, TX, USA
Illinois CancerCare, Peoria, IL, USA
Medical University of South Carolina, Charleston, SC, USA
Mount Sinai Comprehensive Cancer Center, Miami, FL, USA
University Hospitals Case Medical Center, Cleveland, OH, USA
University Hospital Carl-Gustav-Carus of Technical University, Dresden, Germany
BG-Klinikum Bergmannstrost, Halle, Germany
Tufts University School of Medicine, Boston, MA, USA
Stony Brook University, Stony Brook, NY, USA
Hoag Cancer Center, Newport Beach, CA, USA
H. Lee Moffit Cancer Center and Research Institute, Tampa, FL, USA
CHUSHopital Fleurimont, Sherbrooke University, Sherbrooke, QC, Canada
UCSD Health System, UC San Diego, San Diego, CA, USA
Neurochirurgische Klinik University Clinic Hamburg-Eppendorf, Hamburg, Germany
Houston Methodist, Houston, TX, USA
Geisinger Health System, Danville, PA, USA
Klinikum Chemnitz GGMBH, Chemnitz, Germany
Saint Luke’s Cancer Institute, Kansas City, MO, USA
Kaiser Permanente Northern California, Redwood City, CA, USA
Kaiser Permanente Southern California, Los Angeles, CA, USA
University of Kentucky College of Medicine, Lexington, KY, USA
Colorado Neurological Institute, Englewood, CO, USA
Montreal Neurological Institute and Hospital, McGill University, Montreal, Canada
Northwell Hofstra School of Medicine, Lake Success, NY, USA
Department of Neurology, Alvord Brain Tumor Center, University of Washington, Seattle, WA, USA
University College Hospitals, London, UK
Northwest Biotherapeutics Inc., Bethesda, MD, USA
NYU Winthrop Hospital, Mineola, NY, USA


  1. Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D’Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, Aiken R, Chaudhary R, Goldlust SA, Bota DA, Duic P, Grewal J, Elinzano H, Toms SA, Lillehei KO, Mikkelsen T, Walbert T, Abram SR, Brenner AJ, Brem S, Ewend MG, Khagi S, Portnow J, Kim LJ, Loudon WG, Thompson RC, Avigan DE, Fink KL, Geofroy FJ, Lindhorst S, Lutzky J, Sloan AE, Schackert G, Krex D, Meisel H-J, Wu J, Davis RP, Duma C, Etame AB, Mathieu D, Kesari S, Piccioni D, Westphal M, Baskin DS, New PZ, Lacroix M, May S-A, Pluard TJ, Victor T, Green RM, Villano JL, Pearlman M, Petrecca K, Schulder M, Taylor LP, Maida AE, Prins RM, Cloughesy TF, Mulholland P, Bosch ML. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med. 2018;16:142. ArticlePubMedPubMed CentralGoogle Scholar


© The Author(s) 2018